Skip to main content
. 2019 Oct 31;10:1145. doi: 10.3389/fneur.2019.01145

Table 3.

Neuropsychiatric drugs taken by each patient during the study.

Case # OM in use before CE treatment OM in use after CE treatment Summary of changes in OM CE side effects
01f None None No OM None
02m Risperidone + Melatonin None Complete withdrawal None
03m None (used oxcarbazepine before the study) None No OM None
04m None None No OM Nocturia and polyuria
05f None (used several OM before the study) None Complete withdrawal None
06m None None No OM Hyperaemia, sleepiness, and transient increase in core temperature
07m Promethazine + Risperidone Risperidone Partial withdrawal Transient sleepiness
08f Melatonin + Risperidone Risperidone Partial withdrawal + dosage reduction Slight increase in appetite
09m Oxcarbazepine + Risperidone + Levomepromazine Oxcarbazepine + Risperidone + Levomepromazine None None
10m None None No OM None
11m Carbamazepine + Risperidone Risperidone Partial withdrawal + dosage reduction Transient diarrhea at treatment onset
12m Phenobarbital Phenobarbital Complete withdrawal Nocturia
13f Lamotrigine + Topiramate Lamotrigine + Topiramate Dosage reduction Sleepiness and mild irritation
14m Oxcarbazepine + Levetiracetam + Topiramate + Valproate semisodium + Risperidone Topiramate + Risperidone Partial withdrawal + dosage reduction Transient sleepiness and mild irritation when waking up
15m Risperidone + Oxcarbazepine Risperidone + Oxcarbazepine Dosage reduction None

OM, alterations in other prescribed medication after introduction of CE (unaltered: no changes in the use of other medication was made; reduction, reduced the dosage of one or more medication; partial withdrawal, stopped completely the use of one of the medications; withdrawal, stopped completely the use of all other medication with the exception of CE.

f

female patients;

m

male patients.